DexCom, Inc. (NASDAQ:DXCM) Director Sells $223,830.32 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nicholas Augustinos also recently made the following trade(s):

  • On Monday, September 16th, Nicholas Augustinos sold 1,208 shares of DexCom stock. The stock was sold at an average price of $145.49, for a total value of $175,751.92.

NASDAQ DXCM traded up $3.38 during mid-day trading on Friday, hitting $198.08. The stock had a trading volume of 2,580,200 shares, compared to its average volume of 1,138,483. DexCom, Inc. has a 52-week low of $105.05 and a 52-week high of $200.80. The company has a market cap of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64. The company has a 50 day simple moving average of $155.57 and a 200 day simple moving average of $146.29. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm had revenue of $396.30 million during the quarter, compared to the consensus estimate of $348.99 million. During the same period last year, the business posted $0.17 EPS. DexCom’s quarterly revenue was up 48.6% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 0.94 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Allied Advisory Services Inc. purchased a new position in DexCom in the 3rd quarter valued at approximately $271,000. Lyell Wealth Management LP purchased a new position in DexCom in the 3rd quarter valued at approximately $2,999,000. BBVA USA Bancshares Inc. purchased a new position in DexCom in the 3rd quarter valued at approximately $470,000. Massachusetts Financial Services Co. MA increased its stake in DexCom by 9.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 200,499 shares of the medical device company’s stock valued at $29,922,000 after purchasing an additional 16,568 shares in the last quarter. Finally, Tower Research Capital LLC TRC purchased a new position in DexCom in the 3rd quarter valued at approximately $205,000. 96.19% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the company. Robert W. Baird increased their target price on DexCom from $195.00 to $240.00 and gave the stock an “outperform” rating in a research note on Thursday. Canaccord Genuity increased their target price on DexCom from $185.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday. Piper Jaffray Companies increased their target price on DexCom from $182.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday. Bank of America increased their target price on DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Oppenheimer increased their target price on DexCom from $180.00 to $205.00 in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $190.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: What are benefits of a growth and income fund?

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.